The stock has relative volume of 2.38. (NASDAQ:DCTH). Analysts are projecting that the stock will reach $16.00 on a short term (1 year) basis.
Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms. The stock touched its high share price of $6.88 on May 20, 2016 and the stock also touched its Lowest price in the last 52-weeks of trading on Feb 15, 2017 as $0.13.
According to Yahoo Finance, the price target for the company which analysts are aiming is 16.
BioLogic Equity Research Initiated its coverage for Delcath Systems, Inc. The stock's market capitalization is 309777.00, it has a 52-week low of 0.13 and a 52-week high of 6.85. (NASDAQ:DCTH) by some 262,460 shares, 3 decreased positions by 365 and 8 held positions by 167,167.
In an overview of the current analyst recommendations, Buy count is 4 and Overweight is 1 while the number of analysts recommending Sell and Underweight are 1 and 0, respectively. The stock boasts a consensus analyst "Buy" rating with the consensus recommendation standing at 1.70. This showed the surprise of 79.9% in the last quarter earnings. (NASDAQ:DCTH) reported its Actual EPS of $-0.66/share. The difference between Actual EPS and Estimated EPS was 2.63 Percent.More news: HTC 10, HTC One M9, One A9 Android 7.0 Nougat Updates
Delcath Systems, Inc. Gross Margin percentage stands at 72.9% while its Operating Margin for trailing twelve month is 0 percent and Profit margin (ttm) is 0 Percent.
Delcath Systems, Inc.is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. Current stock price is in the upbeat territory taking into account of 20 days moving average with 2.06% and continued bullish run for 50 days moving average with 5.73%. The stock traded with the volume of 9.52 Million shares in the last trading session.
Currently, the company has SMA200 (200-day simple moving average) of -99.27 Percent.
Delcath Systems, Inc. (NASDAQ:DCTH) is now showing its ROA (Return on Assets) of -54.7%. In terms of performance, year to date, the stock is -85.05%. The last session's volume of 2.40 million shares was higher than its average volume of 1.09 million shares. The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT).
The stock now has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. The stock's price is 13.52 and their relative strength index (RSI) stands at 65.29. The stock has a Return on Assets of -54.7 percent, Return on Investment of -176.9 percent and a Return on Equity of -221.1 percent.